Pharmaceutical Waste Disposal: RCRA Subpart P Compliance for Healthcare Facilities

“Pharmaceutical waste disposal” returns two very different worlds of guidance. One is consumer-facing: FDA and DEA drug take-back guidance for people clearing out a home medicine cabinet. The other is institutional: how a hospital pharmacy, clinical research site, health system, or diagnostic lab classifies, accumulates, and disposes of hazardous waste pharmaceuticals under RCRA. This guide covers the second — the compliance framework research administrators, EHS staff, and procurement teams at healthcare and lab facilities actually have to operate under: EPA’s Management Standards for Hazardous Waste Pharmaceuticals, 40 CFR Part 266, Subpart P.

What Makes a Pharmaceutical a RCRA Hazardous Waste

Not every discarded medication is a RCRA hazardous waste. A pharmaceutical becomes hazardous waste under the Resource Conservation and Recovery Act (RCRA) the same way any other discarded material does: if it’s a listed hazardous waste (appears on the P- or U-list in 40 CFR 261.33) or exhibits a hazardous characteristic (ignitability, corrosivity, reactivity, or toxicity per 40 CFR 261.21-261.24). In practice, the pharmaceuticals that trigger the most compliance obligations are:

• P-listed acute hazardous waste — for example warfarin formulations above a specified concentration (P001) and nicotine (P075), though FDA-approved over-the-counter nicotine replacement therapies in original packaging are specifically excluded from the P075 listing.
• U-listed hazardous waste — a range of chemotherapy agents and other pharmaceutical compounds.
• Characteristic waste — most commonly ignitable pharmaceuticals (alcohol-based solutions above the ignitability threshold).

Before Subpart P existed, healthcare facilities had to apply the same generator-status framework used for any other hazardous waste (see CASRAI’s Lab Waste Disposal guide for how that generator-status/satellite-accumulation framework works for general lab chemical waste) — counting pharmaceutical waste toward monthly generation totals that determine VSQG/SQG/LQG status. That created a mismatch: a hospital pharmacy could tip into Large Quantity Generator status, with all its associated training, contingency-planning, and biennial-reporting burden, based on episodic pharmaceutical waste that didn’t reflect its actual chemical-hazard risk profile.

The Two New Generator Categories Subpart P Created

EPA’s hazardous waste pharmaceuticals rule (final rule effective August 21, 2019 in states without their own broader-scope hazardous waste program) replaced that mismatch with a standalone, pharmaceutical-specific framework built around two defined actors:

• Healthcare facility — hospitals, pharmacies (retail, hospital, and long-term-care), clinics, physician and dental offices, veterinary clinics, and similar entities that generate hazardous waste pharmaceuticals in the course of providing patient care, dispensing, or research. Healthcare facilities that are subject to Subpart P no longer have to count their hazardous waste pharmaceuticals toward their generator-status determination for other waste streams — pharmaceutical waste is managed under its own, separate set of standards regardless of what generator category the facility falls into for chemical waste.
• Reverse distributor — a business that receives unused, unexpired pharmaceuticals from healthcare facilities to evaluate them for manufacturer credit. Reverse distributors are now a distinctly regulated category under Subpart P, with their own notification and management-standard obligations, separate from full TSDF (treatment, storage, and disposal facility) permitting.

Non-Creditable vs. Potentially Creditable Hazardous Waste Pharmaceuticals

Subpart P’s central classification question is whether a discarded pharmaceutical still has any manufacturer-credit value:

• Non-creditable hazardous waste pharmaceuticals — expired, used, contaminated, or otherwise unsellable product with no realistic possibility of manufacturer credit. This is what most patient-care-generated pharmaceutical waste is: administered-but-unused doses, discontinued stock past its useful shelf life, partially used vials. It goes straight into on-site accumulation and off-site shipment for disposal (typically incineration at a permitted combustor), using a new, streamlined hazardous waste manifesting/shipping-paper approach rather than the standard multi-copy Uniform Hazardous Waste Manifest process used for other RCRA waste.
• Potentially creditable hazardous waste pharmaceuticals — unused, unexpired, and in original packaging, being sent to a reverse distributor specifically to be evaluated for manufacturer credit. Until the reverse distributor makes a final waste determination, these are managed under a separate set of Subpart P standards rather than triggering full hazardous waste generator obligations at the healthcare facility.

Getting this classification right at the point of generation is the single most consequential decision a pharmacy or lab makes under Subpart P — it determines which set of accumulation, labeling, and shipping requirements applies, and misclassifying non-creditable waste as potentially creditable (or vice versa) is one of the more common findings in state inspections of healthcare facilities.

The Sewering Ban

Subpart P imposes a flat, nationwide prohibition: covered healthcare facilities and reverse distributors may not flush or drain-dispose of any hazardous waste pharmaceutical, regardless of whether it’s listed or characteristic waste, and regardless of concentration. This closed a long-standing practice — pouring unused liquid medications or IV residuals down a sink or toilet — that EPA identified as a meaningful contributor to pharmaceutical contamination detected in surface water and drinking water supplies. This is a bright-line rule with essentially no facility-specific exception: if it’s a hazardous waste pharmaceutical, it does not go down the drain.

Accumulation and Disposal Routes

Once classified, hazardous waste pharmaceuticals still need a defined on-site accumulation and off-site disposal pathway:

• Non-creditable hazardous waste pharmaceuticals are accumulated on-site (in containers meeting Subpart P’s labeling and closure standards) before being shipped off-site — typically to a permitted hazardous waste combustor for incineration, which is the disposal method EPA and most state programs favor for pharmaceutical waste given the destruction-efficiency requirements involved.
• Potentially creditable pharmaceuticals move to a registered reverse distributor first; once that facility makes a hazardous-waste determination on product it can’t credit or resell, it becomes non-creditable hazardous waste pharmaceutical and follows the same off-site disposal path.
• Sharps, chemotherapy-contaminated non-pharmaceutical items (gowns, tubing), and non-hazardous pharmaceutical waste are managed under separate regulated-medical-waste and state solid-waste frameworks, not Subpart P — see the waste-stream decision table in CASRAI’s Lab Waste Disposal guide for how these adjacent streams are typically kept separate rather than commingled.

Controlled Substances: Where DEA Rules Layer on Top of RCRA

A meaningful share of hazardous waste pharmaceuticals are also DEA-controlled substances (for example, certain P-listed compounds). RCRA and DEA regulate destruction of controlled-substance waste separately, and both apply at once where a pharmaceutical is both hazardous waste and a scheduled drug:

• DEA’s own destruction regulations (21 CFR Part 1317) govern who may take custody of and destroy controlled-substance waste, including on-site destruction options and DEA-registered reverse distributor/collector pathways, independent of the pharmaceutical’s RCRA hazardous-waste status.
• A healthcare facility handling a hazardous waste pharmaceutical that is also a controlled substance needs a disposal vendor and process that satisfies both frameworks — RCRA accumulation/labeling/shipping standards under Subpart P, and DEA chain-of-custody/witnessed-destruction requirements for the controlled-substance portion.

This dual-track compliance is one of the most common points of confusion for pharmacy and EHS staff who are fluent in one framework but not the other — procurement teams selecting a pharmaceutical waste vendor should confirm the vendor is equipped to handle both RCRA and DEA-regulated streams, not just one.

Check Your State Before Assuming Subpart P Applies As Written

RCRA is implemented primarily through state hazardous waste programs authorized by EPA, and Subpart P is a broader-scope rule that states must formally adopt into their own authorized programs — it did not take effect automatically nationwide on its federal effective date the way a narrowing (less-stringent) rule change would. A healthcare facility should confirm its state hazardous waste agency’s current adoption status before assuming Subpart P (rather than the prior generator-status-based framework, or a state-specific pharmaceutical waste rule) governs its obligations. Where a state has not yet adopted Subpart P, facilities in that state may still need to manage pharmaceutical waste under the older, generator-status-count-based approach, or under that state’s own equivalent standard — check directly with the state program rather than assuming national uniformity.

How This Differs From Consumer Drug Take-Back Programs

It’s worth being explicit about the boundary, since both topics share search terms: FDA’s drug disposal guidance and DEA’s National Prescription Drug Take Back Day / authorized collector programs (including retail pharmacy take-back kiosks at chains like Walgreens) are aimed at households disposing of unused personal medications, and operate under a different regulatory logic (primarily controlled-substance diversion prevention, not RCRA hazardous waste management). A hospital, clinic, pharmacy, or research facility generating pharmaceutical waste in the course of patient care or research is not covered by consumer take-back guidance — it is a RCRA-regulated healthcare facility or reverse distributor under Subpart P (plus DEA rules where controlled substances are involved), a materially different and more prescriptive compliance obligation.

Compliance Checklist for Procurement and EHS Teams

• Confirm whether your state hazardous waste program has adopted Subpart P, and which framework currently governs your facility.
• Build a point-of-generation classification workflow that sorts pharmaceutical waste into non-creditable vs. potentially creditable at the moment it’s discarded — this decision cascades into everything downstream.
• Confirm your waste hauler/disposal vendor holds the correct permits for hazardous waste pharmaceutical combustion, and, where controlled substances are involved, DEA registration for reverse distribution or destruction under 21 CFR Part 1317.
• Eliminate sewer disposal of any hazardous waste pharmaceutical from your standard operating procedures — this is a zero-exception rule under Subpart P.
• Keep accumulation containers labeled and within the required accumulation-time limits, and retain shipping/disposal documentation the same way you would a hazardous waste manifest.
• Train pharmacy, nursing, and lab staff who physically discard pharmaceuticals — most Subpart P compliance failures happen at the point of generation, not in the paperwork.

Frequently Asked Questions

Is pharmaceutical waste disposal the same as drug take-back?

No. Drug take-back programs (FDA/DEA consumer guidance, pharmacy kiosks, take-back events) are for households disposing of unused personal medication. Hospitals, pharmacies, clinics, and research facilities generating pharmaceutical waste as part of patient care or research are regulated as RCRA healthcare facilities or reverse distributors under 40 CFR Part 266 Subpart P, a separate and more prescriptive framework.

Does all pharmaceutical waste have to be manifested like other hazardous waste?

Subpart P created a streamlined shipping-paper approach for non-creditable hazardous waste pharmaceuticals moving from a healthcare facility to a permitted combustor, distinct from the standard multi-copy Uniform Hazardous Waste Manifest used for most other RCRA waste streams. Potentially creditable pharmaceuticals sent to a reverse distributor are handled under their own separate standard. Confirm the current shipping-paper requirements with your state program and disposal vendor, since state-specific variations exist.

Can hazardous waste pharmaceuticals ever be poured down a drain?

No. Subpart P’s sewering ban is a flat, facility-wide prohibition on drain-disposing any hazardous waste pharmaceutical, with no concentration-based or facility-type exception.

Does Subpart P apply in every state right now?

Only where a state’s authorized hazardous waste program has formally adopted it. Because Subpart P is broader in scope than the standards it replaces, states must adopt it themselves rather than it applying automatically; check current adoption status with your state hazardous waste agency before assuming it governs your facility.

What about chemotherapy waste specifically?

Trace and bulk chemotherapy waste falls within the hazardous waste pharmaceutical framework (RCRA-listed antineoplastic agents commonly fall under Subpart P), though many facilities also separately track chemotherapy waste under “trace” vs. “bulk” distinctions tied to container residue thresholds for handling and PPE purposes, distinct from the RCRA hazardous-waste-pharmaceutical classification itself.